Healthcare
Eisai Co., Ltd.(ESALF)
Live Price
Offline$25.00
+0.00% today
Window Change
-15.91%
Window
Jan 2, 2026 โ Jun 24, 2026
- Market Cap
- $1.32T
- Revenue Growth
- +6.4%
- EPS Growth
- +10.8%
- Dividend Yield
- 3.4%
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 119 bars ยท Jan 2, 2026 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Eisai Co., Ltd. (ESALF) is a Healthcare stock with a market cap of $1.32T and listed on OTC. The stock last traded around $25.00 and down 15.9% across the available one-year price window (Jan 2, 2026 โ Jun 24, 2026). Baseline metrics include revenue growth of +6.4%, EPS growth of +10.8%, a dividend yield of 3.4%. What stands out right now is revenue +6.4%, EPS +10.8%, free cash flow -77.1% with operating margin 5.6% and ROIC 2.8%. The dividend matters to the case here, with a current yield around 3.4%. Valuation already assumes a fairly strong business story at P/E 30.9 and price/sales 1.6. Stock Foundry combines ESALF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+6.4% vs +7.6% peer median
Operating Margin
Below sector median
+5.6% vs +19.4% peer median
P/E
Below sector median
30.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on May 15, 2026 with an EPS surprise of -192.8% and a revenue surprise of +3.9%.
The operating story is still moving forward
Revenue is running at +6.4% and EPS at +10.8%, with operating margin around 5.6%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 31, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +9.4% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 15, 2026 | -192.8% | +0.0% | -2.6% | -15.1% |
2026 Feb 9, 2026 | -17.1% | +0.0% | +23.3% | +14.3% |
2025 Nov 6, 2025 | -26.3% | +0.0% | +7.6% | -10.0% |
Benchmark Edge
ESALF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ESALF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ESALF Max Drawdown
-31.77%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ESALF and SPY.
Company Overview
Eisai Co., Ltd.
Other OTC
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
- Leadership
- Haruo Naito
- IPO Date
- Apr 7, 2011
- Employees
- 11.1k
- Street Address
- 4-6-10, Koishikawa
- Mailing
- Tokyo, 112-8088
- Region
- Tokyo, JP
- Reporting Currency
- USD
- Investor Line
- 81 3 3817 3700
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 30.9
- EV/EBITDA
- 13.8
- Price/Sales
- 1.6
- Price/Book
- 1.5
Growth
- Revenue
- +6.4%
- EPS
- +10.8%
- Free Cash Flow
- -77.1%
Profitability
- Gross Margin
- 77.8%
- Operating Margin
- 5.6%
- Net Margin
- 5.3%
- ROE
- 5.0%
- ROIC
- 2.8%
Balance Sheet
- Debt/Equity
- 0.26
- Current Ratio
- 2.17
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.